A Protocol of Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ).
| Title: | A Protocol of Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ). |
|---|---|
| Authors: | Kim GH; Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.; Pyun JM; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.; Kang D; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea.; Kang SH; Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.; Koh SH; Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.; Kim JS; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Moon SY; Department of Neurology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea.; Moon WJ; Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.; Park YH; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.; Shim Y; Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Yang DW; Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Youn YC; Department of Neurology, Chung-Ang University College of Medicine, Seoul, Korea.; Jung YH; Department of Neurology, Hallym Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea.; Cho H; Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Choi H; Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.; Lim JS; Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Park KH; Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.; Choi SH; Department of Neurology, Inha University College of Medicine, Incheon, Korea. |
| Source: | Dementia and neurocognitive disorders [Dement Neurocogn Disord] 2026 Jan; Vol. 25 (1), pp. 25-41. Date of Electronic Publication: 2026 Jan 15. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Korean Dementia Association Country of Publication: Korea (South) NLM ID: 101600298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2384-0757 (Electronic) Linking ISSN: 17381495 NLM ISO Abbreviation: Dement Neurocogn Disord Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Seoul, Korea : Korean Dementia Association |
| Abstract: | Background and Purpose: To assess the long-term effectiveness, safety, and economic viability of recently approved Alzheimer's disease (AD) therapies, as well as to evaluate the real-world application of novel diagnostics among AD patients with diverse comorbidities, comprehensive real-world data (RWD) analysis is essential. The Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) endeavors to create a registry of RWD derived from clinical practice on new diagnostic methods and therapeutic agents for AD introduced in Korea since 2021.; Methods: Participants must fulfill all the following: 1) be at least 19 years old; 2) be actively receiving, scheduled to initiate, or undergoing evaluation for any AD disease-modifying treatment; 3) have completed amyloid positron emission tomography or cerebrospinal fluid AD immunoassay (a positive result is not essential for participation); 4) have a clinical classification of cognitively unimpaired, mild cognitive impairment, or probable AD dementia. Data generated during routine care is segmented into a minimum dataset, extended dataset, and research-only dataset requiring extra consent. Assessments encompass clinical, cognitive, functional, neurobehavioral, neuroimaging, and biomarker evaluations, in addition to systematic monitoring of new AD treatments and their safety. Data are collected and monitored at baseline, at semiannual intervals during the initial 2 years, and then annually up to 2034. To date, 46 medical centers will participate in JOY-ALZ.; Conclusions: JOY-ALZ is expected to promote understanding of the long-term clinical outcomes, safety, and cost-effectiveness of recently introduced diagnostics and treatments for AD, thereby supporting the progress of precision medicine in AD care and diagnosis.; Trial Registration: ClinicalTrials.gov Identifier: NCT06889818.; (© 2026 Korean Dementia Association.) |
| Competing Interests: | Conflict of Interest: Sung Hoon Kang has served as the editorial board member of the Dementia and Neurocognitive Disorders. However, Sung Hoon Kang has not been involved in the peer reviewer process or decision-making for this article. No other potential conflict of interest relevant to this article was reported. |
| References: | J Psychosom Res. 2004 Sep;57(3):297-305. (PMID: 15507257); Int J Technol Assess Health Care. 1989;5(4):559-75. (PMID: 2634630); Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. (PMID: 25443857); Alzheimers Dement. 2024 Feb;20(2):1214-1224. (PMID: 37932961); Dement Neurocogn Disord. 2018 Mar;17(1):11-22. (PMID: 30906387); Alzheimers Dement. 2024 Dec;20(12):9037-9048. (PMID: 39564918); J Prev Alzheimers Dis. 2025 May;12(5):100160. (PMID: 40189473); Pract Neurol (Fort Wash Pa). 2020 Nov-Dec;2020:24-45. (PMID: 33927583); J Am Med Inform Assoc. 2006 May-Jun;13(3):353-5. (PMID: 16501183); N Engl J Med. 2023 Jan 5;388(1):9-21. (PMID: 36449413); Stat Med. 2005 Jun 15;24(11):1713-23. (PMID: 15724232); J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P47-53. (PMID: 11773223); Neurology. 1993 Nov;43(11):2412-4. (PMID: 8232972); Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250); Dement Neurocogn Disord. 2020 Dec;19(4):161-169. (PMID: 33377669); Alzheimers Dement (Amst). 2021 Jul 20;13(1):e12217. (PMID: 34295959); J Gerontol. 1982 May;37(3):323-9. (PMID: 7069156); Alzheimers Dement. 2014 Nov;10(6):844-52. (PMID: 24798886); Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249); Health Serv Res. 2014 Oct;49(5):1701-20. (PMID: 24779867); Int J Ayurveda Res. 2010 Oct;1(4):274-8. (PMID: 21455458); Drug Discov Ther. 2025 Jul 4;19(3):208-209. (PMID: 40582836); Dement Neurocogn Disord. 2024 Oct;23(4):165-187. (PMID: 39512702); Alzheimers Res Ther. 2017 Dec 15;9(1):98. (PMID: 29246249); Ageing Res Rev. 2024 Nov;101:102481. (PMID: 39236855); Arch Neurol. 1999 Mar;56(3):303-8. (PMID: 10190820); Neurology. 2005 Aug 23;65(4):559-64. (PMID: 16116116); Alzheimers Dement. 2022 Sep;18(9):1694-1695. (PMID: 36094832); Sci Data. 2016 Mar 15;3:160018. (PMID: 26978244); Dement Neurocogn Disord. 2023 Jan;22(1):1-15. (PMID: 36814700); JAMA. 2023 Aug 8;330(6):512-527. (PMID: 37459141); J Prev Alzheimers Dis. 2025 Apr;12(4):100096. (PMID: 39971671); Int Psychogeriatr. 2011 May;23(4):593-601. (PMID: 20843392); Cell. 2019 Oct 3;179(2):312-339. (PMID: 31564456); Int J Technol Assess Health Care. 2013 Apr;29(2):117-22. (PMID: 23587340); Appl Health Econ Health Policy. 2017 Apr;15(2):127-137. (PMID: 28194657); Nat Med. 2022 Dec;28(12):2555-2562. (PMID: 36456833); Cereb Cortex. 2009 Mar;19(3):497-510. (PMID: 18632739); J Geriatr Psychiatry Neurol. 2004 Mar;17(1):32-5. (PMID: 15018695) |
| Contributed Indexing: | Keywords: Alzheimer Disease; Biomarkers; Dataset; Diagnosis; Monoclonal Antibody; Treatment |
| Molecular Sequence: | ClinicalTrials.gov NCT06889818 |
| Entry Date(s): | Date Created: 20260209 Date Completed: 20260209 Latest Revision: 20260211 |
| Update Code: | 20260211 |
| PubMed Central ID: | PMC12876444 |
| DOI: | 10.12779/dnd.2026.25.1.25 |
| PMID: | 41657474 |
| Database: | MEDLINE |
Journal Article